EyeGene Inc (185490) - Total Liabilities

Latest as of March 2026: ₩13.78 Billion KRW ≈ $9.34 Million USD

Based on the latest financial reports, EyeGene Inc (185490) has total liabilities worth ₩13.78 Billion KRW (≈ $9.34 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is EyeGene Inc growing its equity to track the company's year-over-year net asset growth rate.

EyeGene Inc - Total Liabilities Trend (2014–2025)

This chart illustrates how EyeGene Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does EyeGene Inc generate to measure how efficiently the company converts operating cash flow to free cash.

EyeGene Inc Competitors by Total Liabilities

The table below lists competitors of EyeGene Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Ram-On Investments and Holdings Ltd TA:RMN	Israel	ILA16.17 Million
Sam Jung Pulp KO:009770	Korea	₩27.98 Billion
Wha Yu Industrial Co Ltd TW:3419	Taiwan	NT$1.02 Billion
Kaya Limited NSE:KAYA	India	Rs4.01 Billion
Centara Hotels & Resorts Leasehold Property Fund BK:CTARAF	Thailand	฿900.00K
Regional Express Holdings Ltd AU:REX	Australia	AU$580.78 Million
Information and Communication Networks Public Company Limited BK:ICN	Thailand	฿1.23 Billion
Romerike Sparebank OL:ROMER	Norway	Nkr16.57 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down EyeGene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EyeGene Inc (185490) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.37	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.21	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how EyeGene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for EyeGene Inc (2014–2025)

The table below shows the annual total liabilities of EyeGene Inc from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩13.80 Billion ≈ $9.35 Million	-7.91%
2024-12-31	₩14.98 Billion ≈ $10.15 Million	+8.83%
2023-12-31	₩13.77 Billion ≈ $9.33 Million	+0.85%
2022-12-31	₩13.65 Billion ≈ $9.25 Million	-14.79%
2021-12-31	₩16.02 Billion ≈ $10.86 Million	-49.18%
2020-12-31	₩31.53 Billion ≈ $21.37 Million	+11.49%
2019-12-31	₩28.28 Billion ≈ $19.16 Million	-7.88%
2018-12-31	₩30.70 Billion ≈ $20.80 Million	+370.07%
2017-12-31	₩6.53 Billion ≈ $4.43 Million	+175.39%
2016-12-31	₩2.37 Billion ≈ $1.61 Million	+51.49%
2015-12-31	₩1.57 Billion ≈ $1.06 Million	-7.33%
2014-12-31	₩1.69 Billion ≈ $1.14 Million	--

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$45.69 Million

₩67.43 Billion KRW

Market Cap Rank

#22186 Global

#1355 in Korea

Share Price

₩1560.00

Change (1 day)

+6.19%

52-Week Range

₩1193.00 - ₩3355.00

All Time High

₩50300.00